- Home
- SNES vs SNOA Comparison
SNES vs SNOA Comparison
Compare SNES & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNES
- SNOA
- Stock Information
- Founded
- SNES 2004
- SNOA 1999
- Country
- SNES United States
- SNOA United States
- Employees
- SNES N/A
- SNOA N/A
- Industry
- SNES Agricultural Chemicals
- SNOA Biotechnology: Pharmaceutical Preparations
- Sector
- SNES Industrials
- SNOA Health Care
- Exchange
- SNES Nasdaq
- SNOA Nasdaq
- Market Cap
- SNES 6.7M
- SNOA 6.4M
- IPO Year
- SNES 2016
- SNOA 2007
- Fundamental
- Price
- SNES $4.95
- SNOA $2.95
- Analyst Decision
- SNES Strong Buy
- SNOA
- Analyst Count
- SNES 1
- SNOA 0
- Target Price
- SNES $10.00
- SNOA N/A
- AVG Volume (30 Days)
- SNES 262.7K
- SNOA 26.1K
- Earning Date
- SNES 08-07-2025
- SNOA 06-17-2025
- Dividend Yield
- SNES N/A
- SNOA N/A
- EPS Growth
- SNES N/A
- SNOA N/A
- EPS
- SNES N/A
- SNOA N/A
- Revenue
- SNES $1,927,000.00
- SNOA $14,288,000.00
- Revenue This Year
- SNES $130.53
- SNOA $38.54
- Revenue Next Year
- SNES $80.00
- SNOA N/A
- P/E Ratio
- SNES N/A
- SNOA N/A
- Revenue Growth
- SNES 40.15
- SNOA 12.20
- 52 Week Low
- SNES $1.30
- SNOA $1.75
- 52 Week High
- SNES $6.48
- SNOA $9.37
- Technical
- Relative Strength Index (RSI)
- SNES 75.55
- SNOA 44.07
- Support Level
- SNES $3.56
- SNOA $2.81
- Resistance Level
- SNES $5.43
- SNOA $2.95
- Average True Range (ATR)
- SNES 0.50
- SNOA 0.13
- MACD
- SNES 0.15
- SNOA -0.02
- Stochastic Oscillator
- SNES 82.42
- SNOA 28.30
About SNES SenesTech Inc.
SenesTech Inc is a United States-based biotech platform and research company engaged in developing technology for managing animal pest populations through fertility control. The company provides its solutions to the animal market, commercial markets, and food markets. It currently has two product lines of fertility control products: ContraPest and Evolve.
About SNOA Sonoma Pharmaceuticals Inc.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.